http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( D. Munkh-orshikh ),( D. Enkhtuya ),( N. Choijamts ),( Ch. Gantuul ),( O. Baatarkhuu ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: The prevalence of liver cancer in Mongolia is 7 times higher than that of world average, generally caused by HBV and HCV. The most prevalent cause of HCC in Mongolia, HCV, accompanied with liver stiffness and cirrhosis, is an emerging public health issue. Mongolia is one of the first countries that registered Ledipasvir/Sofosbuvir (LDV/SOF) regimen from developing countries. By the support of Access program run by Gilead Sciences, USA, we started HCV treatment program from January 2016. Methods: We followed and evaluated treatment outcome of patients with HCV infection using combination of 90 mg ledispavir/ 400 mg sofosbuvir (manufactured by Gilead Science) in 298 treatment nai¨ve patients. All patients were treated with LDV/SOF for 12 weeks and, their treatment was evaluated by quantitative HCV-RNA assays prior and W (week) 4 and W12 of treatment. Sustained virological response (SVR) after 12 weeks treatment was assessed. Virus genotype analysis using cDNA microarray, liver enzymes, CBC and drug related adverse events were assessed in every patient. The laboratory tests were conducted at National Center of Communicable Diseases and Happy Veritas Laboratories. Results: Out of 298 patients underwent treatment, 138 patients were examined for pre-treatment liver stiffness using Fibroscan. When patients were examined by Fibroscan test, 25% (n = 35) of assessed patients were F0 stage; 13.57% (n = 19) were F1 stage; 10% (n = 14) were F2 stage; 20.71% (n = 29) were F3 stage; and 30.72% (n = 43) were F4 stage. Patients (n = 35) with fibrosis stage F0 were omitted from post-treatment control examinations. The one hundred three patients were selected for further post-treatment fibrosis staging. The twenty three patients were successfully contacted and complied posttreatment Fibroscan scanning. 23/23 (100%) patients achieved SVR12. W, were all genotype 1b. Median ALT level significantly dropped during treatment from 121.19 ± 98.3 IU/L to 33.2 ± 14.7 IU/L and slightly increased by the end of treatment 41.4 ± 18.8 IU/L. The ninety one percent of the patients had improved in liver stiffness while remaining patients were observed increased stiffness. Conclusions: After treatment, 30.43% (n = 7) of patients moved to the F0 stage from liver stiffness. There are many studies that assess liver fibrosis after cure of HCV, but varying numbers were observed. We assess liver stiffness after treatment of HCV in Mongolian population for the first time. Though study population was small, we had 91% of.
( Oidov Baatarkhuu ),( Jae Seung Lee ),( Jazag Amarsanaa ),( Do Young Kim ),( Sang Hoon Ahn ),( Nyamsuren Naranzul ),( Damba Enkhtuya ),( Nagir Choijamts ),( Purev Batbayar ),( Radnaa Otgonbayar ),( B 대한간학회 2021 Clinical and Molecular Hepatology(대한간학회지) Vol.27 No.1
Background/Aims: Ledipasvir/sofosbuvir (LDV/SOF) shows high efficacy and safety in patients with genotype 1-hepatitis C virus (HCV). We aimed to investigate the efficacy and safety of LDV/SOF in real-world Mongolian patients. Methods: Between 2015 to 2019, 23 (0.5%) and 5,005 patients (99.5%) with genotype 1a and 1b HCV, respectively, were treated with a fixed-dose tablet containing 90 mg ledipasvir and 400 mg sofosbuvir for 12 weeks, and 81 patients (1.6%) with previous experience of interferon (IFN)-based treatment received additional 1,000 mg ribavirin. HCV RNA was measured at 4, 12, and 24 weeks after the first dose to determine rapid virologic response, end of treatment response (ETR), and sustained virologic response at 12 weeks after end of treatment (SVR12). Results: Most patients (n=5,008; 99.6%) achieved ETR and SVR12 without virologic relapse. Patients with genotype 1a showed low rates of ETR and SVR12 in only 16 patients (69.6%). There was no significant difference in SVR12 rate between patients regardless of IFN experience (n=81; 1.6%), cirrhosis (n=1,151; 22.9%), HCV RNA >6×10<sup>6</sup> IU/mL (n=866; 17.2%), or liver stiffness >9.6 kPa (n=1,721; 34.2%) (100.0%, 99.3%, 99.4%, and 99.4%, respectively). No severe adverse events (AEs) were reported, and there was no dose reduction or interruption due to AE. The most common AEs were headache (n=472; 9.4%), fatigue (n=306; 6.2%), abdominal discomfort (n=295; 5.9%), and skin rash (n=141; 2.8%). Conclusions: LDV/SOF showed high efficacy and safety for patients with genotype 1, especially 1b HCV, in Mongolia. The real-world data might be applicable to patients in other Asian-Pacific countries. (Clin Mol Hepatol 2021;27:125-135)
Efficacy and Safety of Ledipasvir/Sofosbuvir Treatment of HCV Genotype 1b in Mongolia
( O. Baatarkuu ),( B. Enkhtuvshin ),( N. Lkhaasuren ),( B. Batsukh ),( G. Sarangua ),( D. Enkhtuya ),( N. Choijamts ),( J. Amarsanaa ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: The incident of liver cancer in Mongolia generally caused by HBV and HCV, and it is 7 times higher than that of world average. HCV, the most prevalent cause of HCC in Mongolia, is number one public health issue. Mongolia is one of the first countries that registered ledipasvir/sofosbuvir (LDV/SOF) regimen from developing countries. By the support of Access program run by Gilead Sciences, USA, we started HCV treatment program from January 2016. Methods: We followed and evaluated treatment outcome of patients with HCV infection using combination of 90 mg ledispavir/400 mg sofosbuvir (manufactured by Gilead Science) in 937 treatment naive and 83 treatment experienced patients. All patients were treated with LDV/SOF for 12 weeks and, their treatment was evaluated by quantitative HCV-RNA assays prior and W (week) 4 and W12 of treatment. Sustained virological response (SVR) after 12 weeks treatment was assessed. Virus genotype analysis using cDNA microarray, liver enzymes, CBC and drug related adverse events were assessed in every patient. The laboratory tests were conducted at National Center of Communicable Diseases and Happy Veritas Laboratories. Results: We conducted largest ever (415/1020) HCV genotype (GT) distribution study in Mongolian chronic HCV patients. 96.6% (n = 401) of assessed patients were GT1b; 0.7% (n = 3) were GT2; 0.2% (n = 1) were GT1a and b; 0.9% (n = 4) were GT1b and 2; 0.5% (n = 2) were GT1b and 6; 0.2% (n = 1) were GT5 and 0.2% (n = 1) were GT1b and 80 k mutants respectively. 992/1020 (97.3%) patients achieved SVR12W, 28 (2.7%) patients who did not achieve SVR12 W were all genotype 1b. Median ALT level significantly dropped during treatment from 95.5 ± 84.1 IU/L to 27.2 ± 18.6 IU/L and slightly increased by the end of treatment 42.9 ± 17.4 IU/L. Total of 39 adverse events were observed in 595/1020 patients (58.3%). Single adverse events were observed in 401/1020 (39.3%) whereas 2 and more events were observed in 194 (19%) patients respectively. Unreported adverse events such as partial facial palsy, AFP (alpha-fetoprotein) increase, melasma were observed. Conclusions: Treatment of HCV in Mongolia using all-oral dual DAA was divided in 3 phases due to shortness of drugs and logistics arrangements. We were able to include only stage-one patients in this study. We achieved 97.3% SVR12W for 3 months treatment with LDV/SOF this time. But viral relapse has to be determined repeatedly at weeks 24 and 48 post treatment. All viral relapses (n = 14) and non-responders (n = 14) were GT1 in our study. According to HCV genotype assessment, there was no difference in treatment outcomes between patients who had different genotypes. HCV RNA clearance during treatment was no different than clinical trials, but the slight increase of ALT by the end of treatment was commonly observed. It might have happened due to rebound of immune reaction after clearance of HCV or a drug induced effect.